U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid UMB control number	
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)		
Invention	SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HIV	
As the below na	amed inventor(s), I/we declare that:	
This declaration	n is directed to:	
	The attached application, or	
applicable),	Application No.PCT/IB05/00969, filed on 04/11/2005 (and Preliminary Amendment, if	
	as amended on if applicable);	
sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
I/we have review amendment spec	red and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;	
	WARNING ant is cautioned to avoid submitting personal information in documents filed in a patent application that may	
contribute to ide numbers (other t the USPTO to su USPTO, petition them to the US publication of the or issuance of theapplication is cardauthorizatio notpublicly avail-	entity theft. Personal information such as social security numbers, pank account numbers, or devict call plan a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by apport a petition or an application. If this type of personal information is included in documents submitted to the pers/applicants should consider redacting such personal information from the documents before submitting PTO. Petitioner/applicant is advised that the record of a patent application is available to the public after application (unless a non-publication request in compliance with 37 CPR 1.213(a) is made in the application) a patent. Furthermore, the record from an abandoned application may also be available to the public is referenced in a published application or an issued patent (see 37 CPR 1.14). Checks and credit in forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are able.	
material to pate became availab continuation-in-		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon;		
Full Name of	Inventor(s)	
Inventor 1	Lyn Howard JONES	
Signature	Citizen of Great Britain	
Inventor 2	Shahid MOHAMMED	
Signature	Citizen of Great Britain	

Burden Hour Statement. This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.41. This form is estimated to take 1 minute to complete. This time will vary operating the needs of the individual case. Any comments on the amount of time you are required to complete this time should be set to the Uniformation of the View of V

Additional inventors are being named on

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)		
Title of Invention	SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HIV	
As the below	named inventor(s), I/we declare that:	
This declaration is directed to:		
	The attached application, or	
applicable),	Application No.PCT/IB05/00969, filed on 04/11/2005 (and Preliminary Amendment, if	
	as amended on if applicable);	
I/we believe th sought;	at I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;		
	WARNING  licant is cautioned to avoid submitting personal information in documents filed in a patent application that may	
contribute to identity theft. Personal information such as social security numbers, bank account numbers, cortedit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitionera/applicants is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application also be available to the public of the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit cardauthorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are notpublicly available.		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon;		
	f Inventor(s)	
Inventor 1	Lyn Howard JONES	
Signature	Citizen of	
Inventor 2	Shahid MOHAMMED	
Signature	S M. K	

Burden Hour Statement. This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the invidenda case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information. Officer, U.S. Pattert and Tastemark. Officer, Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Fetherit, Washington, D.C. 20231.

Additional inventors are being named on

Approved for use through 07/31/2006 0MB 0551-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

	erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number	
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)		
Title of St	JUPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HIV	
Invention		
As the below nar	med inventor(s), I/we declare that:	
This declaration	is directed to:	
	The attached application, or	
applicable),	Application No.PCT/IB05/00969, filed on 04/11/2005 (and Preliminary Amendment, if	
	as amended on if applicable);	
I/we believe that I/ sought;	we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	d and understand the contents of the above-identified application, including the claims, as amended by any fically referred to above;	
	WARNING	
contribute to ider numbers (other th the USPTO to sur USPTO, petitione them to the USP publication of the or issuance of a application is ret authorization for publicly and inter- publicly and inter-	nt is cautioned to avoid submitting personal information in documents filed in a patent application that may nitry theft. Personal information such as social security numbers, bank account numbers, or credit card an a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by opport a petition or an application. If this type of personal information is included in documents submitted to the relappicants should consider redacting such personal information from the documents before submitting 'TO. Petitioner/applicant is advised that the record of a patent application is available to the public after application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application patent. Furthermore, the record from an abandoned application may also be available to the public rithe terenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card as PTO-2038 submitted for payment purposes are not retained in the application fle and therefore are not be applicated to the United States Patent and Trademark Office all information known to me/us to be tability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which	
became available continuation-in-pa	e between the filing date of the prior application and the national or PCT International filing date of the art application.	
to be true, and f punishable by fin patent issuing the		
Full Name of Ir	nventor(s)	
Inventor 3	Sandra Dora NEWMAN	
Signature	Citizen of Great Britain	
Inventor 4	Charles Eric MOWBRAY	
Signature	Cilizen of Great Britain	
Additional in	ventors are being named on	

Builden Hour Statement: This collection of information is required by 35 U S C 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confiderability is governed by 35 U S C 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this town should be seen to the Child Information of the Child

Approved for use through 07/31/2006 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patent D. Patent D.

## Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) SUI PHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HIV Title of Invention As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No.PCT/IB05/00969, filed on 04/11/2005 (and Preliminary Amendment, if applicable). as amended on if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought: I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; WARNING Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon; Full Name of Inventor(s) Inventor 5 Matthew Duncan SELBY Mett-Durkly Great Britain Citizen of Signature Inventor 6 Paul Anthony STUPPLE Citizen of Great Britain FC Style Signature

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 163. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 114. This form is estimated to take I must not be semple to the stime with any observation of the public process of the public proce

Additional inventors are being named on

Great Britain

Citizen of

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

Inventor 7

Signature

Nigel Alan SWAIN

Additional inventors are being named on

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) SUI PHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HIV Title of Invention As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No.PCT/IB05/00969, filed on 04/11/2005 (and Preliminary Amendment, if applicable), as amended on if applicable): I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought: I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; WARNING Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon: Full Name of Inventor(s)

Burden Hour Statement This collection of information is required by 35 U.S.C. 115 and 37 CFR 163. The information is used by the public to file (and the PTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 17 CFR 114. This form is estimated to take 1 mixel to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this time will vary depending upon this form should be sent to the Chel information. Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assesshot Commenscenter for Pleants, Washington, D.C. 20231.